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Dear Sir,
We thank Drs. Franceschi and Vaccarella1 for their interest
in our work, and for the additional comments and insights
they provided on the recent apparent epidemic of early papil-
lary thyroid cancers.2
The choice of the scales in ﬁgures of trends in rates in dif-
ferent countries remains arbitrary. The use of different scales
for various countries optimizes the within-country informa-
tion, whereas the use of a single scale for all countries opti-
mizes the between-country comparison; however, it makes
difﬁcult to investigate country-speciﬁc trends, in particular
for those with low rates.
A key observation by Drs. Franceschi and Vaccarella is that
the rise in female thyroid cancer incidence over the last two
decades has been largely heterogeneous across selected high-
income countries providing data, and that there are at least
three countries (Denmark, UK and Japan) where the rise has
been modest in absolute terms—though not in relative ones—
as indicated in Figure 5. Such a moderate rise has already
been observed in selected well-surveilled populations.3 Drs.
Franceschi and Vaccarella attributed the relatively modest
absolute rise in thyroid cancer incidence in Denmark, UK and
Japan to different organization in their health systems and in
their utilization of innovative diagnostic practices, although the
quantiﬁcation of the role of these factors remains elusive.
We agree with Drs. Franceschi and Vaccarella that over-
diagnosis of thyroid cancer can have serious long-term conse-
quences, and that more conservative approaches to the
management of low-risk thyroid cancers are required. We
also agree that the implementation of randomized clinical tri-
als on such management would assist in providing evidence-
based indications.
Acknowledgement
The authors thankMrs I. Garimoldi for editorial assistance.
References
1. Franceschi S, Vaccarella S. Thyroid cancer: An epidemic of disease or an epidemic
of diagnosis? Int J Cancer. 2014 Nov 4. doi: 10.1002/ijc.29311. [Epub ahead of
print].
2. La Vecchia C, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and inci-
dence: A global overview. Int J Cancer. 2014 Oct 4. doi: 10.1002/ijc.29251.
[Epub ahead of print].
3. Levi F, Randimbison L, Te VC, et al. Thyroid cancer in Vaud, Switzerland: An
update. Thyroid 2002;12:163–8.
Grant sponsor: Italian Association for Cancer Research; Grant
number: AIRC Grant N. 10264; Grant sponsor: Swiss Leagues
Against Cancer, and the Swiss Foundation for Research Against
Cancer; Grant number: KFS Grant N. 2437-08-2009
DOI: 10.1002/ijc.29310
History: Received 23 Oct 2014; Accepted 28 Oct 2014; Online 1
Nov 2014
Correspondence to: Cristina Bosetti, Department of Epidemiology,
IRCCS-Istituto di Ricerche Farmacologiche “Mario Negri”, Via Giu-
seppe La Masa 19, 20156 Milan, Italy, Tel.: 139 0239014.526, Fax:
139-0233200231, E-mail: cristina.bosetti@marionegri.it
Le
tt
er
to
th
e
E
di
to
r
Int. J. Cancer: 136, 2740 (2015) VC 2014 UICC
International Journal of Cancer
IJC
